-
Subject Areas on Research
-
3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding.
-
4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors.
-
A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.
-
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
-
ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice.
-
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
-
Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial.
-
Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
-
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
-
Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
-
Albuminuria in chronic heart failure: prevalence and prognostic importance.
-
An enthalpic basis of additivity in biphenyl hydroxamic acid ligands for stromelysin-1.
-
Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor.
-
Angioedema induced by the angiotensin II blocker losartan.
-
Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
-
Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin.
-
Angiotensin II promotes development of the renal microcirculation through AT1 receptors.
-
Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
-
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
-
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
-
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
-
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
-
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
-
Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
-
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
-
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
-
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.
-
Bcl-xL is an oncogenic driver in colorectal cancer.
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
-
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation.
-
Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions.
-
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
-
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
-
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
-
Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3.
-
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
-
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
-
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
-
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
-
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
-
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
-
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
-
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
-
Comparative toxicity of polychlorinated biphenyl and polybrominated biphenyl in the rat liver: light and electron microscopic alterations after subacute dietary exposure.
-
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
-
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
-
Copper complexes containing thiosemicarbazones derived from 6-nitropiperonal: Antimicrobial and biophysical properties.
-
Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.
-
Current-use flame retardants: Maternal exposure and neurodevelopment in children of the CHAMACOS cohort.
-
DIRECT new treatments for diabetic retinopathy.
-
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
-
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
-
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs.
-
Demographic and dietary risk factors in relation to urinary metabolites of organophosphate flame retardants in toddlers.
-
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
-
Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
-
Diphenyl Phosphate-Induced Toxicity During Embryonic Development.
-
Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts.
-
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
-
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
-
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
-
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
-
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
-
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
-
Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
-
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
-
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
-
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
-
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
-
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
-
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.
-
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
-
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
-
Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.
-
Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor.
-
Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction.
-
Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process.
-
From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies.
-
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
-
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
-
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
-
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.
-
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
-
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
-
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
-
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
-
In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.
-
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
-
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time.
-
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
-
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
-
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
-
Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.
-
Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat.
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
-
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
-
Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
-
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
-
Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment?
-
Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites.
-
Losartan in post-transplant erythrocytosis.
-
MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration.
-
Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction.
-
Mechanisms and Models in Heart Failure: A Translational Approach.
-
Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure.
-
Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator.
-
Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF.
-
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
-
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
-
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
-
NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats.
-
New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.
-
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
-
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
-
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
-
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
-
Physiologic role for enhanced renal thromboxane production in murine lupus nephritis.
-
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
-
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.
-
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
-
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
-
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
-
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
-
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
-
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
-
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
-
Reclassifying heart failure: time for disruptive innovation?
-
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
-
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
-
Renal segmental microvascular responses to ANG II in AT1A receptor null mice.
-
Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.
-
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
-
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
-
Role of cholinergic mechanisms in states of wakefulness and sleep.
-
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
-
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
-
Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full?
-
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
-
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
-
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
-
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
-
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
-
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
-
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?
-
Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.
-
Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors.
-
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
-
Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
-
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
-
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
-
The ABCs of managing systolic heart failure: Past, present, and future.
-
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
-
The CHARM programme.
-
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
-
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?
-
The association of urinary phosphorous-containing flame retardant metabolites and self-reported personal care and household product use among couples seeking fertility treatment.
-
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
-
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
-
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.
-
Thromboxane binding and signal transduction in rat glomerular mesangial cells.
-
Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats.
-
Thromboxane receptor blockade reduces renal injury in murine lupus nephritis.
-
Towards establishing indicative values for metabolites of organophosphate ester contaminants in human urine.
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
-
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.